Retreatment with talquetamab and pomalidomide in triple-class-BCMA-GPRC5D refractory myeloma [0.03%]
Kian J Rahbari,Gliceida M Galarza Fortuna,Bhagirathbhai Dholaria et al.
Kian J Rahbari et al.
Louise H Strickland,Hayley G Evans,Olivia C Robinson et al.
Louise H Strickland et al.
Clinical burden and healthcare resource use of congenital thrombotic thrombocytopenic purpura in England: A linked primary and secondary care data analysis [0.03%]
Erin Barker,Will Lester,Heather Riley et al.
Erin Barker et al.
Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra rare haematological disorder. This study aimed to estimate the clinical burden, healthcare resource use (HCRU) and associated costs of cTTP in England using primary and secon...
Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline [0.03%]
英国血液学学会指南：血液科、心脏内科、神经科、肾内科和综合医院门诊早期诊断AL型淀粉样变病
Mamta Garg,Satarupa Choudhuri,Christopher Parrish et al.
Mamta Garg et al.
AL amyloidosis is caused by a plasma cell clone that produces abnormal light chains that misfold and deposit as amyloid fibrils in tissues and thus affect organ function. The survival of patients with systemic amyloid light-chain (AL) amylo...
Quentin Amiot,Anne-Margaux Legland Ép Dejean,Jean-Christian Navarrot et al.
Quentin Amiot et al.
A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study [0.03%]
一项在体弱老年复发或难治性多发性骨髓瘤患者中使用的不含地塞米松的达雷木单抗-伊沙佐米方案：IFM 2018-02Ⅱ期研究结果
Arthur Bobin,Margaret Macro,Cyrille Touzeau et al.
Arthur Bobin et al.
The combination of CD38 immunotherapy and proteasome inhibition has shown synergistic activity. Elderly relapsed or refractory multiple myeloma (RRMM) experience worse outcomes due to variabilities in fitness and higher rates of adverse eve...
High frequency of CD95+/CD45RA- regulatory T cells defines an immunosuppressive profile associated with MDS progression [0.03%]
高频率的CD95+/CD45RA-调节性T细胞定义了与骨髓增生异常综合征进展相关的免疫抑制特征
Romain Vazquez,Nicolas Deredec,Ismael Boussaid et al.
Romain Vazquez et al.
Dynamic interactions between mutated haematopoietic cells and immune cells are key drivers of myelodysplastic neoplasms (MDS) initiation and progression. Regulatory T cells (Tregs) are central mediators of immunosuppression in MDS. We thus ...
Risk of thromboembolism in patients with metastatic renal cell carcinoma treated with combination-based immunotherapy [0.03%]
接受基于联合免疫疗法的转移性肾细胞癌患者的血栓栓塞风险
Yu-Cheng Chang,Hao-Kuen Lin,Joseph Piwowarski et al.
Yu-Cheng Chang et al.